von willebrand disease market insight epidemiology and market forecast

DelveInsight's "Von Willebrand Disease Market Insight, Epidemiology and Market Forecast-2028" report deliver an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Von Willebrand Disease (VWD) in the United States, EU5 (Germany, France, Italy, Spain , and the United Kingdom), and Japan.

Von Willebrand disease is the most common inherited bleeding disorder in the United States, affecting as many as 1 in every 1000 individuals. Von Willebrand disease is often compared to hemophilia, but it is a different condition and has a different pattern of bleeding. It affects both boys and girls equally (while hemophilia mainly affects boys). A parent with VWD has a 50% chance of passing the gene to his or her child.

Our forecasting model has defined the diagnosed prevalent population of Von Willebrand Disease in children and adults. In the US population, people belonging to the latter half of the first decade and the early first half of the second-decade life (i.e., 0-18 years) reported higher diagnosed prevalence than that of people belonging to other age groups. Whereas, in the German population, people belonging to the age group of 19-44 years reported higher diagnosed prevalence than that of people belonging to other age groups.

Geography Covered

The United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2017-2028

Von Willebrand Disease (VWD)—Disease Understanding and Treatment Algorithm

Von Willebrand disease (VWD) is a genetic disorder caused by missing or defective von Willebrand factor (VWF), a clotting protein. VWF binds factor VIII, a key clotting protein, and platelets in blood vessel walls, which help form a platelet plug during the clotting process.

Von Willebrand disease is a heterogeneous disorder and is usually classified into two main types, according to inheritance or acquired forms. Inherited forms are further subdivided into Type 1, 2, and 3 along with a pseudo-VWD. Platelet type disorder which in turn describes their pathophysiology. Type 1 is easily distinguished from type 3 by its milder deficiency and is characterized by a decreased quantity of vWF whereas Type 2 is distinguished on the basis of functional or qualitative deficiencies.

Von Willebrand Disease (VWD) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent Population of Von Willebrand disease (VWD) in 7MM, Gender-Specific Diagnosed Prevalent Population of Von Willebrand disease (VWD) in 7MM, Type-specific Diagnosed Prevalent Cases of Von Willebrand disease (VWD) in 7MM, and Age-specific Diagnosed Prevalent Cases of Von Willebrand disease (VWD) in 7MM) scenario of Von Willebrand disease (VWD) in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain , and the United Kingdom) and Japan from 2017 to 2028.

According to DelveInsight, the total diagnosed prevalent population of Von Willebrand disease (VWD) in seven major markets was 33,758 in 2017. The number of Von Willebrand disease (VWD) cases in the 7MM is expected to increase during the study period of 2017-2028.

Von Willebrand disease (VWD) Drug Chapters

The current therapeutic landscape of Von Willebrand disease can be divided into three major categories based on the class of drugs administered, they are; Non-replacement Therapy using desmopressin (DDAVP) to increase the plasma concentration of vWF, Replacement Therapy using plasma-derived coagulation factor concentrates (Humate-P, Alphanate, Immunate, and Wilate), and Adjunct Therapy using primarily anti-fibrinolytics, such as Tranexamic Acid (Cyclokapron).

A new category of recombinant coagulation factor concentrates -Vonvendi (Shire) has recently entered the replacement therapy segment. The approved (and their generic versions) as well as off-label products that are being used for the treatment of von Willebrand Disease, and contributing toward the market revenue, belong to either of these above-mentioned therapeutic classes.

Non-replacement therapy includes Desmopressin, which has been used as the first-line of treatment mostly for patients suffering from the Type 1 variants and a few Type-2 cases. Stimate (CSL Behring GmbH), DDAVP (Sanofi-Aventis), and Octostim (CSL Behring GmbH) with desmopressin acetate being the active ingredient are some of the drugs which belong to this category. The gradual emergence of virally-inactivated FVIII concentrates containing VWF for the treatment of hemophilia A proved a more optimal replacement therapeutic option for patients with VWD. Currently, they form the second-line of treatment especially during severe bleeding episodes of Type 1 variant as well as Type 2 and Type 3. In the United States, VWD is typically treated with either Humate-P (CSL Behring) or Wilate (Octapharma) or Alphanate (Grifols), which is identical to Fanhdi, made in Spain. Adjunct or supportive therapies mainly include antifibrinolytic agents, such as tranexamic acid (Cyclokapron) and amiococaproic acid (Amicar) which work by inhibiting the interaction of plasminogen with fibrin, thus preventing the degradation of the fibrin clot.

Von Willebrand disease (VWD) Market Outlook

According to DelveInsight, the market of Von Willebrand disease (VWD) in 7MM was found to be approximately USD 397.20 million in 2017. Among the EU5 countries, the United Kingdom had the highest market size with USD 61.62 million in 2017, while Spain had the lowest market size of Von Willebrand Disease with USD 6.37 million in 2017.

Von Willebrand disease (VWD) Drugs Uptake

Overall, the increasing diagnosed prevalence of the disease along with the promising expanded recombinant therapies will fuel the market during the forecasted period of 2019-2028 with some of the major players in the VWD treatment market being Shire Plc. (earlier Baxalta), CSL Behring, LFB Biomedicaments SA, Octapharma AG, and Grifols SA.

The recent launch of Shire's Vonvendi/Veyvondi in the US and the expected launch in EU in 2019 have the potential to create a significant positive shift in the von Willebrand Disease market size. Expected launch of Wilfactin (LFB Biomedicaments) in 2021 (will file in the US) will also create a positive impact on the VWD market in US.

Von Willebrand disease (VWD) Report Insights

Patient Population by total diagnosed cases

Gender-specific diagnosed population

Type-specific diagnosed population

Age-specific diagnosed population

Therapeutic Approaches

Pipeline Analysis

Market Size and Trends

Market Opportunities

Impact of upcoming Therapies

Von Willebrand disease (VWD) Report Key Strengths

10-Year Forecast

7MM Coverage

Epidemiology Segmentation

Drugs Uptake

Highly Analyzed Market

Key Cross Competition

Von Willebrand disease (VWD) Report Assessment

Current Treatment Practices

Unmet Needs

Detailed Pipeline Product Profiles

Market Attractiveness

Market Drivers and Barriers

Key Benefits

This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Von Willebrand disease (VWD) market.

Organize sales and marketing efforts by identifying the best opportunities for Von Willebrand disease (VWD) market.

To understand the future market competition in the Von Willebrand disease (VWD) market.